Project Grant HT94252410737
Award Date
7/1/24
Completion Date
6/30/27
Dollars Obligated
$277K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Tallahassee, FL 32306, USA
Similar Awards
This federal Project Grant award, in the amount of $915,000.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award is intended to "IMPROVE TARGETED OVARIAN CANCER THERAPY USING THE NOVEL NOTCH PATHWAY INHIBITOR AURANOFIN" at the University of New Mexico Health Sciences Center (UNM HSC) over the period of July 1, 2024 to June 30, 2027. UNM HSC, a leading academic medical center and health sciences institution,...
This $1,144,000 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at the University of Oklahoma Health Sciences Center to develop a drug targeting ORP4 as a precision treatment for ovarian cancer. The research aims to transform healthcare for military service members, veterans, and the broader public through innovative investigations spanning basic, applied, and translational domains....
This Project Grant award, valued at $750,000.00, was issued on May 1, 2025 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research by the University of Houston System to investigate "Circulating Immune Complexes as Biomarkers for Early Detection and Monitoring of Ovarian Cancer." The research aims to transform healthcare for military service members, veterans, and the broader public through innovative...
The Defense Health Agency has awarded a $968,400 Project Grant to Mayo Clinic to develop a personalized approach to treating drug-resistant ovarian cancer. The grant, which began on June 1, 2024, and will run through May 31, 2028, is funded under the Military Medical Research and Development program (CFDA 12.420). This program supports biomedical research to improve the health and care of military service members, veterans, and their families. Through this award, Mayo Clinic will leverage its...
This federal Project Grant award of $551,881 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research at the University of Florida on a novel therapeutic approach for BRCA-mutated triple-negative breast cancer. The research aims to evaluate the dual inhibition of PARP and IL-6 as a potential treatment. The award period is from July 1, 2024 to June 30, 2027, providing funding to conduct this innovative, multi-year...
The University of South Florida (USF) was awarded a $409,064 Project Grant by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct a "MULTIOMIC EVALUATION OF OVARIAN CANCER RESPONSES TO HEATED INTRAPERITONEAL CHEMOTHERAPY HIPEC". This 3-year award, with a performance period from September 30, 2024 to August 31, 2027, will support research to evaluate the use of multiomics analysis to better understand how ovarian cancer...
The Defense Health Agency awarded Dana-Farber Cancer Institute a $1,046,135 project grant under the Military Medical Research and Development program to conduct research titled "Drugging the Undruggable: Programming Ovarian Cancer Cells as the Next-Generation Immunotherapy." The three-year award runs from May 15, 2023 to May 14, 2026. As the prime recipient, Dana-Farber will leverage its expertise in tumor biology, immunology and drug development to research new therapies for ovarian...
The U.S. Defense Health Agency awarded a $1,562,257 project grant under the Military Medical Research and Development program (CFDA 12.420) to The Ohio State University. The grant supports research to target de novo pyrimidine synthesis as a potential treatment for ovarian cancer. The project will involve collaboration between researchers at The Ohio State University and the University of South Florida, who will design experiments to investigate the role of pyrimidine synthesis in ovarian cancer...
The Defense Health Agency awarded Rutgers, The State University of New Jersey a $942,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support targeted chemotherapeutic and immunotherapeutic research for drug-resistant ovarian cancer. The three-year award beginning April 1, 2023 will fund Rutgers Biomedical and Health Sciences' investigation into medical solutions for this treatment-resistant form of ovarian cancer through innovative research...
The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...